Global Ultra Short Acting Insulin Market Growth 2022-2028
- LP 4946850
- 103 Pages
- April 2022
- Pharmaceuticals
The United States Ultra Short Acting Insulin market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Ultra Short Acting Insulin market, reaching US$ million by the year 2028. As for the Europe Ultra Short Acting Insulin landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Ultra Short Acting Insulin players cover Eli Lilly and Company, Gan & Lee Pharmaceuticals, Novo Nordisk, and Wockhardt, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Ultra Short Acting Insulin market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Insulin Lispro
Insulin Aspart
Insulin Glulisine
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Eli Lilly and Company
Gan & Lee Pharmaceuticals
Novo Nordisk
Wockhardt
Ypsomed
Tonghua Dongbao
Sanofi
United Laboratory
Jiangsu Wanbang
B. Braun
Becton, Dickinson
Biocon
Biodel
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ultra Short Acting Insulin Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Ultra Short Acting Insulin by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Ultra Short Acting Insulin by Country/Region, 2017, 2022 & 2028
2.2 Ultra Short Acting Insulin Segment by Type
2.2.1 Insulin Lispro
2.2.2 Insulin Aspart
2.2.3 Insulin Glulisine
2.3 Ultra Short Acting Insulin Sales by Type
2.3.1 Global Ultra Short Acting Insulin Sales Market Share by Type (2017-2022)
2.3.2 Global Ultra Short Acting Insulin Revenue and Market Share by Type (2017-2022)
2.3.3 Global Ultra Short Acting Insulin Sale Price by Type (2017-2022)
2.4 Ultra Short Acting Insulin Segment by Application
2.4.1 Type 1 Diabetes
2.4.2 Type 2 Diabetes
2.4.3 Gestational Diabetes
2.5 Ultra Short Acting Insulin Sales by Application
2.5.1 Global Ultra Short Acting Insulin Sale Market Share by Application (2017-2022)
2.5.2 Global Ultra Short Acting Insulin Revenue and Market Share by Application (2017-2022)
2.5.3 Global Ultra Short Acting Insulin Sale Price by Application (2017-2022)
3 Global Ultra Short Acting Insulin by Company
3.1 Global Ultra Short Acting Insulin Breakdown Data by Company
3.1.1 Global Ultra Short Acting Insulin Annual Sales by Company (2020-2022)
3.1.2 Global Ultra Short Acting Insulin Sales Market Share by Company (2020-2022)
3.2 Global Ultra Short Acting Insulin Annual Revenue by Company (2020-2022)
3.2.1 Global Ultra Short Acting Insulin Revenue by Company (2020-2022)
3.2.2 Global Ultra Short Acting Insulin Revenue Market Share by Company (2020-2022)
3.3 Global Ultra Short Acting Insulin Sale Price by Company
3.4 Key Manufacturers Ultra Short Acting Insulin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ultra Short Acting Insulin Product Location Distribution
3.4.2 Players Ultra Short Acting Insulin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Ultra Short Acting Insulin by Geographic Region
4.1 World Historic Ultra Short Acting Insulin Market Size by Geographic Region (2017-2022)
4.1.1 Global Ultra Short Acting Insulin Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Ultra Short Acting Insulin Annual Revenue by Geographic Region
4.2 World Historic Ultra Short Acting Insulin Market Size by Country/Region (2017-2022)
4.2.1 Global Ultra Short Acting Insulin Annual Sales by Country/Region (2017-2022)
4.2.2 Global Ultra Short Acting Insulin Annual Revenue by Country/Region
4.3 Americas Ultra Short Acting Insulin Sales Growth
4.4 APAC Ultra Short Acting Insulin Sales Growth
4.5 Europe Ultra Short Acting Insulin Sales Growth
4.6 Middle East & Africa Ultra Short Acting Insulin Sales Growth
5 Americas
5.1 Americas Ultra Short Acting Insulin Sales by Country
5.1.1 Americas Ultra Short Acting Insulin Sales by Country (2017-2022)
5.1.2 Americas Ultra Short Acting Insulin Revenue by Country (2017-2022)
5.2 Americas Ultra Short Acting Insulin Sales by Type
5.3 Americas Ultra Short Acting Insulin Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ultra Short Acting Insulin Sales by Region
6.1.1 APAC Ultra Short Acting Insulin Sales by Region (2017-2022)
6.1.2 APAC Ultra Short Acting Insulin Revenue by Region (2017-2022)
6.2 APAC Ultra Short Acting Insulin Sales by Type
6.3 APAC Ultra Short Acting Insulin Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Ultra Short Acting Insulin by Country
7.1.1 Europe Ultra Short Acting Insulin Sales by Country (2017-2022)
7.1.2 Europe Ultra Short Acting Insulin Revenue by Country (2017-2022)
7.2 Europe Ultra Short Acting Insulin Sales by Type
7.3 Europe Ultra Short Acting Insulin Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ultra Short Acting Insulin by Country
8.1.1 Middle East & Africa Ultra Short Acting Insulin Sales by Country (2017-2022)
8.1.2 Middle East & Africa Ultra Short Acting Insulin Revenue by Country (2017-2022)
8.2 Middle East & Africa Ultra Short Acting Insulin Sales by Type
8.3 Middle East & Africa Ultra Short Acting Insulin Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ultra Short Acting Insulin
10.3 Manufacturing Process Analysis of Ultra Short Acting Insulin
10.4 Industry Chain Structure of Ultra Short Acting Insulin
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ultra Short Acting Insulin Distributors
11.3 Ultra Short Acting Insulin Customer
12 World Forecast Review for Ultra Short Acting Insulin by Geographic Region
12.1 Global Ultra Short Acting Insulin Market Size Forecast by Region
12.1.1 Global Ultra Short Acting Insulin Forecast by Region (2023-2028)
12.1.2 Global Ultra Short Acting Insulin Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ultra Short Acting Insulin Forecast by Type
12.7 Global Ultra Short Acting Insulin Forecast by Application
13 Key Players Analysis
13.1 Eli Lilly and Company
13.1.1 Eli Lilly and Company Company Information
13.1.2 Eli Lilly and Company Ultra Short Acting Insulin Product Offered
13.1.3 Eli Lilly and Company Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Eli Lilly and Company Main Business Overview
13.1.5 Eli Lilly and Company Latest Developments
13.2 Gan & Lee Pharmaceuticals
13.2.1 Gan & Lee Pharmaceuticals Company Information
13.2.2 Gan & Lee Pharmaceuticals Ultra Short Acting Insulin Product Offered
13.2.3 Gan & Lee Pharmaceuticals Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Gan & Lee Pharmaceuticals Main Business Overview
13.2.5 Gan & Lee Pharmaceuticals Latest Developments
13.3 Novo Nordisk
13.3.1 Novo Nordisk Company Information
13.3.2 Novo Nordisk Ultra Short Acting Insulin Product Offered
13.3.3 Novo Nordisk Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Novo Nordisk Main Business Overview
13.3.5 Novo Nordisk Latest Developments
13.4 Wockhardt
13.4.1 Wockhardt Company Information
13.4.2 Wockhardt Ultra Short Acting Insulin Product Offered
13.4.3 Wockhardt Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Wockhardt Main Business Overview
13.4.5 Wockhardt Latest Developments
13.5 Ypsomed
13.5.1 Ypsomed Company Information
13.5.2 Ypsomed Ultra Short Acting Insulin Product Offered
13.5.3 Ypsomed Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Ypsomed Main Business Overview
13.5.5 Ypsomed Latest Developments
13.6 Tonghua Dongbao
13.6.1 Tonghua Dongbao Company Information
13.6.2 Tonghua Dongbao Ultra Short Acting Insulin Product Offered
13.6.3 Tonghua Dongbao Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Tonghua Dongbao Main Business Overview
13.6.5 Tonghua Dongbao Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Ultra Short Acting Insulin Product Offered
13.7.3 Sanofi Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 United Laboratory
13.8.1 United Laboratory Company Information
13.8.2 United Laboratory Ultra Short Acting Insulin Product Offered
13.8.3 United Laboratory Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 United Laboratory Main Business Overview
13.8.5 United Laboratory Latest Developments
13.9 Jiangsu Wanbang
13.9.1 Jiangsu Wanbang Company Information
13.9.2 Jiangsu Wanbang Ultra Short Acting Insulin Product Offered
13.9.3 Jiangsu Wanbang Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Jiangsu Wanbang Main Business Overview
13.9.5 Jiangsu Wanbang Latest Developments
13.10 B. Braun
13.10.1 B. Braun Company Information
13.10.2 B. Braun Ultra Short Acting Insulin Product Offered
13.10.3 B. Braun Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 B. Braun Main Business Overview
13.10.5 B. Braun Latest Developments
13.11 Becton, Dickinson
13.11.1 Becton, Dickinson Company Information
13.11.2 Becton, Dickinson Ultra Short Acting Insulin Product Offered
13.11.3 Becton, Dickinson Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Becton, Dickinson Main Business Overview
13.11.5 Becton, Dickinson Latest Developments
13.12 Biocon
13.12.1 Biocon Company Information
13.12.2 Biocon Ultra Short Acting Insulin Product Offered
13.12.3 Biocon Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Biocon Main Business Overview
13.12.5 Biocon Latest Developments
13.13 Biodel
13.13.1 Biodel Company Information
13.13.2 Biodel Ultra Short Acting Insulin Product Offered
13.13.3 Biodel Ultra Short Acting Insulin Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Biodel Main Business Overview
13.13.5 Biodel Latest Developments
14 Research Findings and Conclusion
Table 1. Ultra Short Acting Insulin Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Ultra Short Acting Insulin Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Insulin Lispro
Table 4. Major Players of Insulin Aspart
Table 5. Major Players of Insulin Glulisine
Table 6. Global Ultra Short Acting Insulin Sales by Type (2017-2022) & (K Units)
Table 7. Global Ultra Short Acting Insulin Sales Market Share by Type (2017-2022)
Table 8. Global Ultra Short Acting Insulin Revenue by Type (2017-2022) & ($ million)
Table 9. Global Ultra Short Acting Insulin Revenue Market Share by Type (2017-2022)
Table 10. Global Ultra Short Acting Insulin Sale Price by Type (2017-2022) & (US$/Unit)
Table 11. Global Ultra Short Acting Insulin Sales by Application (2017-2022) & (K Units)
Table 12. Global Ultra Short Acting Insulin Sales Market Share by Application (2017-2022)
Table 13. Global Ultra Short Acting Insulin Revenue by Application (2017-2022)
Table 14. Global Ultra Short Acting Insulin Revenue Market Share by Application (2017-2022)
Table 15. Global Ultra Short Acting Insulin Sale Price by Application (2017-2022) & (US$/Unit)
Table 16. Global Ultra Short Acting Insulin Sales by Company (2020-2022) & (K Units)
Table 17. Global Ultra Short Acting Insulin Sales Market Share by Company (2020-2022)
Table 18. Global Ultra Short Acting Insulin Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Ultra Short Acting Insulin Revenue Market Share by Company (2020-2022)
Table 20. Global Ultra Short Acting Insulin Sale Price by Company (2020-2022) & (US$/Unit)
Table 21. Key Manufacturers Ultra Short Acting Insulin Producing Area Distribution and Sales Area
Table 22. Players Ultra Short Acting Insulin Products Offered
Table 23. Ultra Short Acting Insulin Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Ultra Short Acting Insulin Sales by Geographic Region (2017-2022) & (K Units)
Table 27. Global Ultra Short Acting Insulin Sales Market Share Geographic Region (2017-2022)
Table 28. Global Ultra Short Acting Insulin Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Ultra Short Acting Insulin Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Ultra Short Acting Insulin Sales by Country/Region (2017-2022) & (K Units)
Table 31. Global Ultra Short Acting Insulin Sales Market Share by Country/Region (2017-2022)
Table 32. Global Ultra Short Acting Insulin Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Ultra Short Acting Insulin Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Ultra Short Acting Insulin Sales by Country (2017-2022) & (K Units)
Table 35. Americas Ultra Short Acting Insulin Sales Market Share by Country (2017-2022)
Table 36. Americas Ultra Short Acting Insulin Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Ultra Short Acting Insulin Revenue Market Share by Country (2017-2022)
Table 38. Americas Ultra Short Acting Insulin Sales by Type (2017-2022) & (K Units)
Table 39. Americas Ultra Short Acting Insulin Sales Market Share by Type (2017-2022)
Table 40. Americas Ultra Short Acting Insulin Sales by Application (2017-2022) & (K Units)
Table 41. Americas Ultra Short Acting Insulin Sales Market Share by Application (2017-2022)
Table 42. APAC Ultra Short Acting Insulin Sales by Region (2017-2022) & (K Units)
Table 43. APAC Ultra Short Acting Insulin Sales Market Share by Region (2017-2022)
Table 44. APAC Ultra Short Acting Insulin Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Ultra Short Acting Insulin Revenue Market Share by Region (2017-2022)
Table 46. APAC Ultra Short Acting Insulin Sales by Type (2017-2022) & (K Units)
Table 47. APAC Ultra Short Acting Insulin Sales Market Share by Type (2017-2022)
Table 48. APAC Ultra Short Acting Insulin Sales by Application (2017-2022) & (K Units)
Table 49. APAC Ultra Short Acting Insulin Sales Market Share by Application (2017-2022)
Table 50. Europe Ultra Short Acting Insulin Sales by Country (2017-2022) & (K Units)
Table 51. Europe Ultra Short Acting Insulin Sales Market Share by Country (2017-2022)
Table 52. Europe Ultra Short Acting Insulin Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Ultra Short Acting Insulin Revenue Market Share by Country (2017-2022)
Table 54. Europe Ultra Short Acting Insulin Sales by Type (2017-2022) & (K Units)
Table 55. Europe Ultra Short Acting Insulin Sales Market Share by Type (2017-2022)
Table 56. Europe Ultra Short Acting Insulin Sales by Application (2017-2022) & (K Units)
Table 57. Europe Ultra Short Acting Insulin Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Ultra Short Acting Insulin Sales by Country (2017-2022) & (K Units)
Table 59. Middle East & Africa Ultra Short Acting Insulin Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Ultra Short Acting Insulin Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Ultra Short Acting Insulin Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Ultra Short Acting Insulin Sales by Type (2017-2022) & (K Units)
Table 63. Middle East & Africa Ultra Short Acting Insulin Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Ultra Short Acting Insulin Sales by Application (2017-2022) & (K Units)
Table 65. Middle East & Africa Ultra Short Acting Insulin Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Ultra Short Acting Insulin
Table 67. Key Market Challenges & Risks of Ultra Short Acting Insulin
Table 68. Key Industry Trends of Ultra Short Acting Insulin
Table 69. Ultra Short Acting Insulin Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Ultra Short Acting Insulin Distributors List
Table 72. Ultra Short Acting Insulin Customer List
Table 73. Global Ultra Short Acting Insulin Sales Forecast by Region (2023-2028) & (K Units)
Table 74. Global Ultra Short Acting Insulin Sales Market Forecast by Region
Table 75. Global Ultra Short Acting Insulin Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Ultra Short Acting Insulin Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Ultra Short Acting Insulin Sales Forecast by Country (2023-2028) & (K Units)
Table 78. Americas Ultra Short Acting Insulin Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Ultra Short Acting Insulin Sales Forecast by Region (2023-2028) & (K Units)
Table 80. APAC Ultra Short Acting Insulin Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Ultra Short Acting Insulin Sales Forecast by Country (2023-2028) & (K Units)
Table 82. Europe Ultra Short Acting Insulin Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Ultra Short Acting Insulin Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Middle East & Africa Ultra Short Acting Insulin Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Ultra Short Acting Insulin Sales Forecast by Type (2023-2028) & (K Units)
Table 86. Global Ultra Short Acting Insulin Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Ultra Short Acting Insulin Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Ultra Short Acting Insulin Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Ultra Short Acting Insulin Sales Forecast by Application (2023-2028) & (K Units)
Table 90. Global Ultra Short Acting Insulin Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Ultra Short Acting Insulin Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Ultra Short Acting Insulin Revenue Market Share Forecast by Application (2023-2028)
Table 93. Eli Lilly and Company Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 94. Eli Lilly and Company Ultra Short Acting Insulin Product Offered
Table 95. Eli Lilly and Company Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 96. Eli Lilly and Company Main Business
Table 97. Eli Lilly and Company Latest Developments
Table 98. Gan & Lee Pharmaceuticals Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 99. Gan & Lee Pharmaceuticals Ultra Short Acting Insulin Product Offered
Table 100. Gan & Lee Pharmaceuticals Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 101. Gan & Lee Pharmaceuticals Main Business
Table 102. Gan & Lee Pharmaceuticals Latest Developments
Table 103. Novo Nordisk Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 104. Novo Nordisk Ultra Short Acting Insulin Product Offered
Table 105. Novo Nordisk Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 106. Novo Nordisk Main Business
Table 107. Novo Nordisk Latest Developments
Table 108. Wockhardt Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 109. Wockhardt Ultra Short Acting Insulin Product Offered
Table 110. Wockhardt Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 111. Wockhardt Main Business
Table 112. Wockhardt Latest Developments
Table 113. Ypsomed Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 114. Ypsomed Ultra Short Acting Insulin Product Offered
Table 115. Ypsomed Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 116. Ypsomed Main Business
Table 117. Ypsomed Latest Developments
Table 118. Tonghua Dongbao Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 119. Tonghua Dongbao Ultra Short Acting Insulin Product Offered
Table 120. Tonghua Dongbao Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 121. Tonghua Dongbao Main Business
Table 122. Tonghua Dongbao Latest Developments
Table 123. Sanofi Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 124. Sanofi Ultra Short Acting Insulin Product Offered
Table 125. Sanofi Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 126. Sanofi Main Business
Table 127. Sanofi Latest Developments
Table 128. United Laboratory Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 129. United Laboratory Ultra Short Acting Insulin Product Offered
Table 130. United Laboratory Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 131. United Laboratory Main Business
Table 132. United Laboratory Latest Developments
Table 133. Jiangsu Wanbang Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 134. Jiangsu Wanbang Ultra Short Acting Insulin Product Offered
Table 135. Jiangsu Wanbang Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 136. Jiangsu Wanbang Main Business
Table 137. Jiangsu Wanbang Latest Developments
Table 138. B. Braun Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 139. B. Braun Ultra Short Acting Insulin Product Offered
Table 140. B. Braun Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 141. B. Braun Main Business
Table 142. B. Braun Latest Developments
Table 143. Becton, Dickinson Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 144. Becton, Dickinson Ultra Short Acting Insulin Product Offered
Table 145. Becton, Dickinson Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 146. Becton, Dickinson Main Business
Table 147. Becton, Dickinson Latest Developments
Table 148. Biocon Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 149. Biocon Ultra Short Acting Insulin Product Offered
Table 150. Biocon Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 151. Biocon Main Business
Table 152. Biocon Latest Developments
Table 153. Biodel Basic Information, Ultra Short Acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 154. Biodel Ultra Short Acting Insulin Product Offered
Table 155. Biodel Ultra Short Acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 156. Biodel Main Business
Table 157. Biodel Latest Developments
List of Figures
Figure 1. Picture of Ultra Short Acting Insulin
Figure 2. Ultra Short Acting Insulin Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ultra Short Acting Insulin Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Ultra Short Acting Insulin Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Ultra Short Acting Insulin Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Insulin Lispro
Figure 10. Product Picture of Insulin Aspart
Figure 11. Product Picture of Insulin Glulisine
Figure 12. Global Ultra Short Acting Insulin Sales Market Share by Type in 2021
Figure 13. Global Ultra Short Acting Insulin Revenue Market Share by Type (2017-2022)
Figure 14. Ultra Short Acting Insulin Consumed in Type 1 Diabetes
Figure 15. Global Ultra Short Acting Insulin Market: Type 1 Diabetes (2017-2022) & (K Units)
Figure 16. Ultra Short Acting Insulin Consumed in Type 2 Diabetes
Figure 17. Global Ultra Short Acting Insulin Market: Type 2 Diabetes (2017-2022) & (K Units)
Figure 18. Ultra Short Acting Insulin Consumed in Gestational Diabetes
Figure 19. Global Ultra Short Acting Insulin Market: Gestational Diabetes (2017-2022) & (K Units)
Figure 20. Global Ultra Short Acting Insulin Sales Market Share by Application (2017-2022)
Figure 21. Global Ultra Short Acting Insulin Revenue Market Share by Application in 2021
Figure 22. Ultra Short Acting Insulin Revenue Market by Company in 2021 ($ Million)
Figure 23. Global Ultra Short Acting Insulin Revenue Market Share by Company in 2021
Figure 24. Global Ultra Short Acting Insulin Sales Market Share by Geographic Region (2017-2022)
Figure 25. Global Ultra Short Acting Insulin Revenue Market Share by Geographic Region in 2021
Figure 26. Global Ultra Short Acting Insulin Sales Market Share by Region (2017-2022)
Figure 27. Global Ultra Short Acting Insulin Revenue Market Share by Country/Region in 2021
Figure 28. Americas Ultra Short Acting Insulin Sales 2017-2022 (K Units)
Figure 29. Americas Ultra Short Acting Insulin Revenue 2017-2022 ($ Millions)
Figure 30. APAC Ultra Short Acting Insulin Sales 2017-2022 (K Units)
Figure 31. APAC Ultra Short Acting Insulin Revenue 2017-2022 ($ Millions)
Figure 32. Europe Ultra Short Acting Insulin Sales 2017-2022 (K Units)
Figure 33. Europe Ultra Short Acting Insulin Revenue 2017-2022 ($ Millions)
Figure 34. Middle East & Africa Ultra Short Acting Insulin Sales 2017-2022 (K Units)
Figure 35. Middle East & Africa Ultra Short Acting Insulin Revenue 2017-2022 ($ Millions)
Figure 36. Americas Ultra Short Acting Insulin Sales Market Share by Country in 2021
Figure 37. Americas Ultra Short Acting Insulin Revenue Market Share by Country in 2021
Figure 38. United States Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 39. Canada Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 40. Mexico Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 41. Brazil Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 42. APAC Ultra Short Acting Insulin Sales Market Share by Region in 2021
Figure 43. APAC Ultra Short Acting Insulin Revenue Market Share by Regions in 2021
Figure 44. China Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 45. Japan Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 46. South Korea Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 47. Southeast Asia Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 48. India Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 49. Australia Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 50. Europe Ultra Short Acting Insulin Sales Market Share by Country in 2021
Figure 51. Europe Ultra Short Acting Insulin Revenue Market Share by Country in 2021
Figure 52. Germany Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 53. France Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 54. UK Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 55. Italy Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 56. Russia Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 57. Middle East & Africa Ultra Short Acting Insulin Sales Market Share by Country in 2021
Figure 58. Middle East & Africa Ultra Short Acting Insulin Revenue Market Share by Country in 2021
Figure 59. Egypt Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 60. South Africa Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 61. Israel Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 62. Turkey Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 63. GCC Country Ultra Short Acting Insulin Revenue Growth 2017-2022 ($ Millions)
Figure 64. Manufacturing Cost Structure Analysis of Ultra Short Acting Insulin in 2021
Figure 65. Manufacturing Process Analysis of Ultra Short Acting Insulin
Figure 66. Industry Chain Structure of Ultra Short Acting Insulin
Figure 67. Channels of Distribution
Figure 68. Distributors Profiles
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
